Berdagang Vir Biotechnology VIR

Jual
 Beli

VirBiotechnology carta live

5m 15m 30m 1h 4h 1d 1w

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

Berita Terkini

Frances Wang 2025 Apr 22, 16:00

Commodity market today: Crude Oil Fluctuates as OPEC+ Modifies Production Goals

Commodities
Tommy Yap 2025 Apr 22, 16:00

Morning Note: Trump Calms Fed Fears; Tesla Disappoints; UK Trade Talks Begin

Morning Note Tech
Frances Wang 2025 Apr 21, 16:00

Stock Market Today: Dow, S&P 500, Nasdaq Fall as Trump Rips Fed Chair Powell

Stocks Indices
Tommy Yap 2025 Apr 21, 16:00

Morning Note: Trump's Fed Pressure Slams Stocks, Boosts Gold; Oil Recovers

Morning Note Stocks Commodities
Frances Wang 2025 Apr 20, 16:00

Gold Price Today: XAU/USD Over $3,350 on Trump's Tariff Policies Uncertainty

Commodities
Tommy Yap 2025 Apr 20, 16:00

Morning Note: Dollar Falls on Trump-Fed Fears; Japan in US Trade Talks; China holds rates

Morning Note Forex
Tommy Yap 2025 Apr 19, 16:00

Week Ahead: Growth, Inflation, and Consumer Trends in Focus

Forex Indices
Frances Wang 2025 Apr 17, 16:00

Stock market today: Nifty above 24,400, Sensex up 309 points

Stocks Indices

Maklumat

Sebaran nilai

0.05

Spread (%)

0.8389 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran ditutup

Khamis

13:31 - 19:59

Isnin

13:31-19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Jumaat

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

800771200

Saham Tertunggak

138064000

Tarikh Pendapatan (Seterusnya)

0000-00-00

Hasil Div

Tarikh Selepas Dividen

Kadar dividen tahunan depan

0

Hasil dividen tahunan depan

0

EPS

-3.83

Ketahui lebih lanjut mengenai instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Instrumen Berkaitan

Aset
Jual
Beli
Perubahan (%):

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang
Instrumen Berkaitan
Trustpilot